8-K current report · filed Jul 28, 2026

NEOGENOMICS INC (NEO) 8-K Current Report: July 28, 2026

Item 2.02Item EX-99.1NEO overview

Short answer

NEOGENOMICS INC (NEO) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results released July 28, 2026.

NEOGENOMICS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 fiscal 2026 results released July 28, 2026
  • Detailed financial results and management commentary available in Exhibit 99.1
  • Earnings disclosure furnished under Regulation FD, not filed under Exchange Act Section 18 liability

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $202M, up 11% YoY, with clinical revenue up 14% and NGS growth of 26%
  • Adjusted EBITDA $14M, up 36%, while adjusted gross margin reached 48.1%, up from 45.4%
  • GAAP net income $2M versus a $45M loss, helped by an $11M debt extinguishment gain
  • FY2026 guidance raised: revenue $802M-$806M and adjusted EBITDA $56M-$58M
  • $316M convertible offering at 0.75% due 2032 funded repurchase of approximately $276M of 2028 notes and $25M of stock repurchases

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other NEOGENOMICS INC 8-K filings

Get the next NEO 8-K as it lands

Follow NEO for push alerts, or ask the research agent what this filing means.